Evidence map›Paper›PMID 42630994›Full record

ArticleJournal of community hospital internal medicine perspectives2026

A Case of Nivolumab-Induced Bullous Pemphigoid-Successfully Treated with Rituximab.

Rawa Amin, Neel Ranpura, Haris Hatic

Abstract readCase Reports
In one paragraph

Article in Journal of community hospital internal medicine perspectives, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Rawa AminNorthside Hospital Gwinnett, Lawrenceville, GA, USA.
Neel RanpuraSeckinger High School, Buford, GA, USA.
Haris HaticSuburban Hematology and Oncology Associates, Buford, GA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Drug-associated bullous pemphigoid (DABP) refers to cases of bullous pemphigoid caused by exposure to various drugs. We present a case of nivolumab (a programmed cell death-ligand 1 (PD-L1) inhibitor) induced bullous pemphigoid in a patient treated for classic Hodgkin's lymphoma, presenting four months after cessation of therapy. The patient demonstrated minimal clinical response to steroids and methotrexate. Following initiation of rituximab, the patient experienced rapid improvement of the rash with no further disease progression.

Indexed as

Bullous pemphigoidDrug-reactionHodgkinLymphomaNivolumabProgrammed death ligand 1Rituximab

Identifiers

PMID42630994
PMCPMC13496475

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.